Sunny Pharmtech Announces Strategic Collaboration with Company D for Lymphoma Drug Development
On August 27, Sunny Pharmtech announced a strategic collaboration with Company D to develop a drug targeting Lymphoma. The partnership will initially focus on the U.S. market, with plans to gradually expand into global markets. Sunny and Company D have collaborated on other products sold in the U.S., and this new agreement marks a further deepening of their cooperation, aiming to provide a stable, high-quality, and continuous supply of essential medicines to patients in the U.S. and around the world.
Romidepsin Injection is developed by using in-house technology in Sunny. Following signing of the agreement, Sunny is expected to receive upfront payments and milestone payments based on the development progress. Once the product is launched, both parties will collaborate on marketing and share the subsequent revenue.